A Limited Institution Study of the Local and Systemic Effects of Intraperitoneal Chemotherapy in the Treatment of Previously-Untreated, Invasive Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

Trial Information

A Limited Institution Study of the Local and Systemic Effects of Intraperitoneal Chemotherapy in the Treatment of Previously-Untreated, Invasive Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

OBJECTIVES:

- Determine the feasibility of obtaining peritoneal fluid, peritoneal washings, and
peripheral blood in patients receiving intraperitoneal (IP) chemotherapy for ovarian
cancer at multiple institutions.

- Assess the recovery and viability of peripheral blood mononuclear cells and immune cell
subsets in peritoneal fluid and washings.

- Assess the amount of peritoneal fluid that can be obtained pre-treatment and at
specified time points during the course of IP chemotherapy.

- Quantify the type and number of cells in peritoneal fluid, peritoneal washings, and
blood recovered from women before and during treatment with platinum- and taxane-based
IP chemotherapy.

- Determine the levels of immunomodulatory cytokines in peritoneal fluid, peritoneal
washings, and blood recovered from women before and during treatment with platinum- and
taxane-based IP chemotherapy.

- Generate exploratory information on the impact of platinum- and taxane-based IP
chemotherapy on immunomodulatory cytokines and tumor-associated alterations in cell
phenotypes of peritoneal fluid, peritoneal washings, and blood.

- Determine the feasibility of obtaining peritoneal fluid, peritoneal washings, and
peripheral blood in patients receiving intravenous (IV) chemotherapy for ovarian cancer
at multiple institutions (limited to patients that receive an IP catheter at the time
of surgery and the catheter is left in by the investigator, but are subsequently
treated with IV chemotherapy).

- Assess the amount of peritoneal fluid that can be obtained pre-treatment and at
specified time points during the course of IV chemotherapy.

- Assess the recovery and viability of peripheral blood mononuclear cells and immune cell
subsets in peritoneal fluid and washings.

- Quantify the type and number of immune cells in peritoneal fluid, peritoneal washings,
and blood recovered from women before and during treatment with platinum- and
taxane-based IV chemotherapy.

- Determine levels of immunomodulatory cytokines in peritoneal fluid, peritoneal
washings, and blood recovered from women before and during treatment with platinum- and
taxane-based IV chemotherapy.

- Generate exploratory information on the impact of platinum- and taxane-based IV
chemotherapy on immunomodulatory cytokines tumor-associated alterations in cell
phenotypes of peritoneal fluid, peritoneal washings, and blood.

- Explore whether there is a relationship between immune cell populations measured in
peripheral blood, peritoneal fluid, and peritoneal washings AND immune cell subsets
measured by immunohistochemistry in archival formalin-fixed, paraffin-embedded tumor
tissue.

OUTLINE: This is a multicenter study. Patients are assigned to a group based on which arm of
treatment they are randomized to receive on GOG-0252.

- Group A (IP catheter removed): Archival formalin-fixed, paraffin-embedded tumor
(collected during previous surgery), peritoneal fluid, peritoneal wash, and blood (for
cell, plasma, and serum isolation) samples are collected before course one and blood
(for cell, plasma, and serum isolations) is collected before courses two and three for
translational research.

- Group B (IP catheter in place): Archival formalin-fixed, paraffin-embedded tumor
(collected during previous surgery), peritoneal fluid, peritoneal wash, and blood (for
cell, plasma, and serum isolation) samples are collected before course one and
peritoneal fluid, peritoneal wash, and blood (for cell, plasma, and serum isolations)
before courses two and three for translational research.